[HTML][HTML] Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

…, MJ Mamounas, JR Eastham, PK Kimes, SP Williams… - Nature Medicine, 2022 - nature.com
Immune checkpoint inhibitors (ICIs), by reinvigorating CD8 + T cell mediated immunity, have
revolutionized cancer therapy. Yet, the systemic CD8 + T cell distribution, a potential …

Antibody positron emission tomography imaging in anticancer drug development

LE Lamberts, SP Williams… - Journal of Clinical …, 2015 - ascopubs.org
More than 50 monoclonal antibodies (mAbs), including several antibody–drug conjugates,
are in advanced clinical development, forming an important part of the many molecularly …

Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET

…, M Darwish, JR Junutula, SP Williams… - Nuclear medicine and …, 2010 - Elsevier
Three thiol reactive reagents were developed for the chemoselective conjugation of
desferrioxamine (Df) to a monoclonal antibody via engineered cysteine residues (thio-trastuzumab). …

An anti-B7-H4 antibody–drug conjugate for the treatment of breast cancer

…, N Koppada, L Roth, SP Williams… - Molecular …, 2015 - ACS Publications
B7-H4 has been implicated in cancers of the female reproductive system and investigated
for its possible use as a biomarker for cancer, but there are no preclinical studies to …

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model

CV Pastuskovas, EE Mundo, SP Williams… - Molecular cancer …, 2012 - AACR
Both human epidermal growth factor receptor 2 (HER-2/neu) and VEGF overexpression
correlate with aggressive phenotypes and decreased survival among breast cancer patients. …

Evidence for a protective role of metallothionein-1 in focal cerebral ischemia

…, R Gerlai, JT Palmer, SP Williams… - Proceedings of the …, 1999 - National Acad Sciences
Metallothioneins (MTs) are a family of metal binding proteins that have been proposed to
participate in a cellular defense against zinc toxicity and free radicals. In the present study, we …

ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment

…, J Voortman, OS Hoekstra, SP Williams… - Clinical Cancer …, 2016 - AACR
Purpose: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers,
making it a potential drug target. We performed an 89 Zr-PET imaging study with …

Quantification of tumor tissue populations by multispectral analysis

…, AL Ross, J Ross, SP Williams… - … in Medicine: An …, 2004 - Wiley Online Library
Tumor heterogeneity complicates the quantification of a therapeutic response by MRI. To
address this issue, a novel approach has been developed that combines MR diffusion imaging …

[HTML][HTML] Evaluation of a 3-hydroxypyridin-2-one (2, 3-HOPO) based macrocyclic chelator for 89Zr4+ and its use for immunoPET imaging of HER2 positive model of …

…, A Ogasawara, AN Vanderbilt, HS Gill, SP Williams… - Theranostics, 2016 - ncbi.nlm.nih.gov
A novel octadentate 3-hydroxypyridin-2-one (2, 3-HOPO) based di-macrocyclic ligand was
evaluated for chelation of 89 Zr; subsequently, it was used as a bi-functional chelator for …

Secondary reduction in the apparent diffusion coefficient of water, increase in cerebral blood volume, and delayed neuronal death after middle cerebral artery …

…, JT Palmer, SP Williams… - Journal of Cerebral …, 1999 - journals.sagepub.com
It has been reported recently that very delayed damage can occur as a result of focal cerebral
ischemia induced by vascular occlusion of short duration. With use of diffusion-, T2-, and …